Lucid Diagnostics (NASDAQ:LUCD) Lifted to Hold at Zacks Investment Research

Lucid Diagnostics (NASDAQ:LUCD – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday, Zacks.com reports. According to Zacks, “Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. Lucid Diagnostics Inc. is based in […]

Related Keywords

United States ,America , ,Lucid Diagnostics Company Profile Get Rating ,Lucid Diagnostics Inc ,Virtu Financial ,Zacks Investment Research ,America Corp ,Susquehanna International Group ,Needham Company ,Cantor Fitzgerald ,Charles Schwab Investment Management Inc ,Canaccord Genuity Group ,Pavmed Inc ,Lucid Diagnostics ,Get Rating ,Genuity Group ,Schwab Investment Management ,Diagnostics Company Profile ,Diagnostics Inc ,Nasdaq Lucd ,Elucd ,Medical ,Upgrade ,